Year All2024202320222021202020192018 August 28, 2024 Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences August 13, 2024 Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights July 31, 2024 Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis June 24, 2024 Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors June 4, 2024 Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference June 3, 2024 Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary May 20, 2024 Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors May 16, 2024 Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights April 4, 2024 Contineum Therapeutics Announces Pricing of Initial Public Offering
August 13, 2024 Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
July 31, 2024 Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis
June 4, 2024 Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
June 3, 2024 Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary
May 16, 2024 Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights